Literature DB >> 2974318

Abnormal expression of the MOS proto-oncogene in human thyroid medullary carcinoma.

M H Parkar1, J M Seid, B M Stringer, S Ingemansson, N Woodhouse, M H Goyns.   

Abstract

We have been studying the expression of a range of proto-oncogenes in human thyroid tumour tissue by using Northern blot analysis. We have demonstrated the expression of a MOS mRNA of 1 kb in all thyroid samples. Furthermore, in a medullary carcinoma sample we also observed additional mRNA species of 1.7 and 2.2 kb. Southern blot analysis of DNA prepared from the same tumour sample did not reveal a rearrangement of the gene. These findings are the first report of MOS expression in any human tissue, and indicate that MOS oncogene activation might be important in the development of some thyroid tumours.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2974318     DOI: 10.1016/0304-3835(88)90169-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

Review 1.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

Authors:  F M Michiels; S Chappuis; B Caillou; A Pasini; M Talbot; R Monier; G M Lenoir; J Feunteun; M Billaud
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

3.  Detection of the H-RAS oncogene in human thyroid anaplastic carcinomas.

Authors:  B M Stringer; J M Rowson; M H Parkar; J M Seid; P R Hearn; D Wynford-Thomas; S Ingemansson; N Woodhouse; M H Goyns
Journal:  Experientia       Date:  1989-04-15

4.  Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas.

Authors:  K A de Foy; S A Gayther; W H Colledge; S Crockett; I V Scott; M J Evans; B A Ponder
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.